Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.
Latest from Joseph Haas
Arcus is ending development of its TIGIT-targeted antibody domvanalimab after it was determined a Phase III study would not show a survival benefit in gastrointestinal cancers.
Triple agonist retatrutide yielded 28.7% weight loss at 68 weeks, besting Zepbound’s Phase III data, while also showing benefit in knee osteoarthritis pain.
Pfizer’s Phase III data show an 8.6-month increase in progression-free survival for Tukysa as first-line maintenance treatment of HER2+ breast cancer, a setting where the standard of care hasn’t changed since 2012.
With its M&A war chest diminished and still seeking to add to its weight-management pipeline, Pfizer obtains an oral GLP-1 analog from Fosun subsidiary YaoPharma.
With three approved drugs and volixibat in pivotal studies for two cholestatic liver diseases, Mirum is betting $570m in cash and equity to pick up Bluejay’s Phase III hepatitis D candidate.
Beyond the fierce Lilly and Novo Nordisk competition in the weight-management market, other deep-pocketed firms are advancing their novel candidates and seeking a way in through dealmaking.